Description

Book Synopsis
Haematological malignancies, defined as cancers that affect the blood, bone marrow, and lymph nodes, represent a serious health care challenge for oncologists. Chapter One focuses on cytogenetic and molecular markers and summarizes their importance in identification, treatment and prognosis in patients with myeloproliferative neoplasms. Chapter Two details the efficacy of treatment of myeloid hematologic malignancies with isocitrate dehydrogenase mutations by inhibitors of this enzyme. Chapter Three describes the use of Selinexor and other drugs for the treatment of hematologic malignancies. Chapter Four explains the utility of poly(ADP-ribose) polymerase inhibitors in the treatment of myelodysplastic syndrome and acute myeloid leukaemia.

Table of Contents
Preface; Molecular and Cytogenetic Markers and Their Clinical Implications in Myeloproliferative Neoplasms; Treatment of Myeloid Hematologic Malignancies with Isocitrate Dehydrogenase Mutations by Inhibitors of This Enzyme; Inhibition of Nuclear Export as a New Therapy in Hematologic Malignancies; Poly(adp-Ribose) Polymerase Inhibitors in the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia; Index.

New Research on Hematological Malignancies

    Product form

    A Paperback / softback by David K. Gioia

    £62.04

    Includes FREE delivery

    RRP £72.99 – you save £10.95 (15%)

    Order before 4pm tomorrow for delivery by Tue 1 Sep 2026.

    1 in stock

      Trusted by thousands of customers. See 2,385+ Customer Reviews

      View other formats and editions of New Research on Hematological Malignancies by David K. Gioia

      Book details

      Publisher Nova Science Publishers Inc
      Published 1 October 2021
      ISBN-13 9781536199550
      978-1536199550
      ISBN-10 1536199559
      Also in:
      Haematology Oncology

      Description

      Book Synopsis
      Haematological malignancies, defined as cancers that affect the blood, bone marrow, and lymph nodes, represent a serious health care challenge for oncologists. Chapter One focuses on cytogenetic and molecular markers and summarizes their importance in identification, treatment and prognosis in patients with myeloproliferative neoplasms. Chapter Two details the efficacy of treatment of myeloid hematologic malignancies with isocitrate dehydrogenase mutations by inhibitors of this enzyme. Chapter Three describes the use of Selinexor and other drugs for the treatment of hematologic malignancies. Chapter Four explains the utility of poly(ADP-ribose) polymerase inhibitors in the treatment of myelodysplastic syndrome and acute myeloid leukaemia.

      Table of Contents
      Preface; Molecular and Cytogenetic Markers and Their Clinical Implications in Myeloproliferative Neoplasms; Treatment of Myeloid Hematologic Malignancies with Isocitrate Dehydrogenase Mutations by Inhibitors of This Enzyme; Inhibition of Nuclear Export as a New Therapy in Hematologic Malignancies; Poly(adp-Ribose) Polymerase Inhibitors in the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia; Index.

      Recently viewed products

      © 2026 Book Curl

        • American Express
        • Apple Pay
        • Diners Club
        • Discover
        • Google Pay
        • Maestro
        • Mastercard
        • PayPal
        • Shop Pay
        • Union Pay
        • Visa

        Login

        Forgot your password?

        Don't have an account yet?
        Create account